Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 4/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.42 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.42 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | EDNRA | P25101 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9671914 | 0.87 | AGTR1 (0.58) | AGTR1LTB4R2 | |
| SCHEMBL30929294 | 0.77 | AGTR1 (0.43) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL7942076 | 0.76 | AGTR1 (0.46) | AGTR1LTB4R2AGTR2 | |
| SCHEMBL13127115 | 0.75 | AGTR1 (0.44) | AGTR1LTB4R2 | |
| SCHEMBL9081604 | 0.75 | AGTR1 (0.46) | AGTR1LTB4R2AGTR2 | |
| Irbesartan SCHEMBL2212239 | 0.75 | AGTR1 (0.74) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| Irbesartan SCHEMBL4246 | 0.75 | AGTR1 (0.74) | AGTR1LTB4R2AGTR2ABCC3ABCC4 | |
| SCHEMBL9082860 | 0.74 | AGTR1 (0.45) | AGTR1LTB4R2AGTR2 | |
| SCHEMBL9084369 | 0.74 | AGTR1 (0.45) | AGTR1LTB4R2AGTR2 | |
| Irbesartan SCHEMBL4726034 | 0.74 | AGTR1 (0.73) | AGTR1LTB4R2AGTR2ABCC3ABCC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0726072-A2 | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-14 | — | — | EP | claimed |
| JP-8245385-A | — | — | None | — | — | JP | disclosed |
| US-8796331-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2014-08-05 | — | — | US | disclosed |
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2013-06-20 | — | — | US | disclosed |
| US-8404744-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2013-03-26 | — | — | US | disclosed |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2012-06-07 | — | — | US | disclosed |
| US-8101659-B2 | Methods of treatment and pharmaceutical composition | NOVARTIS AG (CH) | 2012-01-24 | — | — | US | disclosed |
| US-7468390-B2 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS AG (CH) | 2008-12-23 | — | — | US | disclosed |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | disclosed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | disclosed |
| JP-H08245385-A | TREATMENT OF HYPERTENSION AND CONGESTIVE HEART FAILURE | BRISTOL MYERS SQUIBB CO | 1996-09-24 | — | — | JP | disclosed |
| EP-0726072-A2 | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-14 | — | — | EP | disclosed |
| EP-0726072-A2 | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | AGTR1 3/4885LTB4R2 1816/4885AGTR2 5/4885 |
| US-20130158086-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | AGTR1 2/4885LTB4R2 2125/4885AGTR2 4/4885 |
| US-20120138506-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, MME, ACE | AGTR1 4/4885LTB4R2 1382/4885AGTR2 5/4885 |
| US-20130158085-A1 | METHODS OF TREATMENT AND PHARMACEUTICAL COMPOSITION | REN, AGTR1, TTR | AGTR1 2/4885LTB4R2 2125/4885AGTR2 4/4885 |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | REN, AGTR1, AGTR2 | AGTR1 2/4885LTB4R2 1815/4885AGTR2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.